Clinical trial NCT00525161: Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer
Official title: A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patients With Advanced Breast Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: breast cancer
Sorafenib
Nexavar
Endocrine Therapy
Lead sponsor: University of Kentucky
Sponsor class: OTHER
Collaborators: name: Bayer
First posted: 2007-09-05
Enrollment: 11
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the clinical response rate to sorafenib when added to existing endocrine therapy in patients with advanced breast cancer.

Detailed description: A pilot Phase II study adding sorafenib to endocrine therapy in 11 patients with metastatic estrogen receptor-positive breast cancer was conducted. Primary end point was response by Response Evaluation Criteria in Solid Tumors (RECIST) after 3 months of sorafenib. Secondary end points included safety, time to progression and biomarker modulation. The study closed early owing to slow accrual.

Eligibility criteria: Inclusion Criteria:

* All subjects must be female.
* Age ≥ 18 years old.
* Histologically proven carcinoma of the breast.
* Estrogen receptor and/or Progesterone positive disease.
* Metastatic or locally advanced disease.
* Patients on a preexisting endocrine agent for at least 3 months before enrollment.
* Have residual measurable disease after

  1. maximal response to endocrine therapy or
  2. no response to endocrine therapy or
  3. progressive non-visceral disease on endocrine therapy.
* Must be able to provide a tumor block from either the primary or metastatic site, if available.
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.
* Adequate organ function.

Exclusion Criteria:

* Patients with rapidly progressive disease on endocrine therapy who would otherwise be candidates for chemotherapy.
* Other coexisting malignancies, with the exception of basal cell carcinoma or cervical carcinoma in situ.
* Prior use of anti-angiogenic agents.
* As judged by the investigator, uncontrolled intercurrent illness.
* Known brain metastasis. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis.
* Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.
* Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.
* Known or suspected allergy to sorafenib or any agent given in the course of this trial.
* A serious non-healing wound or ulcer.
* Evidence or history of bleeding diathesis or coagulopathy.
* Major surgery, open biopsy or significant traumatic injury within the 4 weeks prior to the first dose of the study drug.
* Pulmonary hemorrhage/bleeding event ≥ Common Toxicity Criteria for Adverse Effects (CTCAE) Grade 2 within the 4 weeks prior to the first dose of study drug.
* Pregnancy
* Any condition that impairs patient's ability to swallow whole pills.
* Documented malabsorption problem.

Primary outcomes:
measure: Response Rate
timeFrame: 12 weeks after treatment & 8 weeks after initial documentation of response
Secondary outcomes:
measure: Time to Progression
timeFrame: continuously
measure: Clinical Benefit Rate
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: Suleiman Massarweh, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Massarweh S, Moss J, Wang C, Romond E, Slone S, Weiss H, Karabakhtsian RG, Napier D, Black EP. Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer. Future Oncol. 2014 Dec;10(15):2435-48. doi: 10.2217/fon.14.99.